This is an optimized Investor Page for viewing on mobile devices, to view our entire Investor Relations site click here.
Sep 2, 2010
Long Term Data Presented at ESC 2010 Shed Further Light on the Benefit of the CYPHER(R) Sirolimus Drug-Eluting Stent Compared to the ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
> Read More
Aug 31, 2010
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
> Read More
Aug 31, 2010
CORDIS announces results of ten-year CYPHER® Sirolimus-eluting coronary stent follow-up
> Read More
Aug 30, 2010
Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain
> Read More
Aug 26, 2010
DePuy Orthopaedics Voluntarily Recalls ASR(TM) Hip System
> Read More
Oct 19, 2010 at 8:30 AM
Johnson & Johnson Third Quarter 2010 Earnings Meeting
Jan 25, 2011 at 8:30 AM
Johnson & Johnson Fourth Quarter and Full-Year 2010 Earnings Meeting
© 1992-2008 JNJ Systems, Inc. All rights reserved.